General Biologicals Corporation (TPEX:4117)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
4.150
0.00 (0.00%)
Mar 12, 2026, 2:59 PM CST
Market Cap252.42M -77.5%
Revenue (ttm)251.38M +3.7%
Net Income-243.60M
EPS-4.07
Shares Out60.83M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,436,997
Average Volume842,050
Open4.000
Previous Close4.150
Day's Range4.000 - 4.400
52-Week Range3.500 - 24.900
Beta0.50
RSI10.41
Earnings DateApr 24, 2026

About General Biologicals

General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening services for hepatitis and HIV; and biomaterial, such as antibody biomaterials and human plasma. Additionally, it offers a range of oral care products... [Read more]

Sector Healthcare
Founded 1984
Employees 81
Stock Exchange Taipei Exchange
Ticker Symbol 4117
Full Company Profile

Financial Performance

In 2024, General Biologicals's revenue was 251.93 million, a decrease of -4.87% compared to the previous year's 264.83 million. Losses were -220.82 million, 11.1% more than in 2023.

Financial Statements